Akebia Therapeutics to Showcase Kidney Disease Pipeline in April R&D Day
Event summary
- Akebia Therapeutics will host a virtual R&D Day on April 2, 2026, to discuss its kidney disease pipeline.
- The event will feature scientific experts James A. Tumlin, MD, V. Michael Holers, MD, and Jonathan Barratt, MD, PhD, FRCP.
- Key pipeline programs include Praliciguat (Phase 2 for FSGS), AKB-097 (planned Phase 2 for rare kidney diseases), and AKB-9090 (Phase 1 for AKI).
- AKB-097 is planned to enter a Phase 2 basket trial in rare kidney diseases in the second half of 2026.
- AKB-9090 is set to enter a Phase 1 clinical trial in acute kidney injury associated with cardiac surgery in the first half of 2026.
The big picture
Akebia Therapeutics is positioning itself as a key player in the kidney disease space with a robust pipeline of clinical-stage programs. The upcoming R&D Day highlights the company's focus on addressing unmet needs in rare kidney diseases and acute kidney injury, which are areas of significant medical and commercial interest. The involvement of prominent scientific experts underscores the strategic importance of these programs in the broader biopharmaceutical landscape.
What we're watching
- Pipeline Progress
- The success of AKB-097 in entering Phase 2 trials will be critical for Akebia's strategy in rare kidney diseases.
- Clinical Execution
- The pace at which AKB-9090 advances through Phase 1 trials will indicate Akebia's ability to address acute kidney injury.
- Market Differentiation
- How Akebia positions its pipeline against competitors in the kidney disease space will shape its market potential.
Related topics